James Investment Research Inc. Boosts Stake in Integer Holdings Co. (NYSE:ITGR)

James Investment Research Inc. lifted its holdings in Integer Holdings Co. (NYSE:ITGR) by 7.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 12,290 shares of the medical equipment provider’s stock after purchasing an additional 824 shares during the quarter. James Investment Research Inc.’s holdings in Integer were worth $1,598,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ITGR. Contravisory Investment Management Inc. lifted its holdings in Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares in the last quarter. Quest Partners LLC boosted its holdings in Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares during the last quarter. GAMMA Investing LLC increased its stake in Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Integer during the 1st quarter worth approximately $106,000. Finally, Innealta Capital LLC acquired a new position in shares of Integer during the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Oppenheimer assumed coverage on Integer in a research report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price target for the company. Benchmark upped their target price on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Piper Sandler reiterated an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Truist Financial decreased their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, Bank of America boosted their price target on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Price Performance

Shares of ITGR opened at $126.47 on Friday. The firm has a 50-day simple moving average of $128.00 and a two-hundred day simple moving average of $121.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. Integer Holdings Co. has a 1-year low of $82.65 and a 1-year high of $133.53. The stock has a market cap of $4.24 billion, a PE ratio of 39.03, a P/E/G ratio of 1.87 and a beta of 1.08.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. During the same quarter in the previous year, the company earned $1.27 earnings per share. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, analysts forecast that Integer Holdings Co. will post 5.33 EPS for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.